New research has shown that there are genetic factors that drive which breast cancers will relapse and metastasize and which will not, and the identification of these factors may help clinicians identify patients at higher risk for recurrence.
Breast Cancer Targets
Tracking tumor DNA in the blood of early breast cancer patients following surgery predicted relapse nearly 8 months earlier than conventional imaging.
Testing women for non-BRCA gene mutations that can confer breast or ovarian cancer risk has clinical management consequences for both the women and their family members.
Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.
The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
A randomized trial failed to show non-inferiority of 6 months of adjuvant trastuzumab compared with the standard 12 months for HER2-positive breast cancer.
MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast cancer patients.
As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.
The addition of bevacizumab to endocrine therapy did not prolong survival in postmenopausal women with advanced HER2-negative, HR–positive breast cancer.